Eli Lilly and Company (NYSE:LLY) Shares Climb 2.5% – Here’s Why

Shares of Eli Lilly and Company (NYSE:LLY) were up 2.5% on Wednesday. The company traded as high as $1,206.63 and last traded at $1,186.95. Approximately 2,294,125 shares changed hands during trading, a decline of 23% from the average session volume of 2,971,630 shares. The stock had previously closed at $1,157.49.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Next-generation obesity treatments could extend Lilly’s growth runway. Analysts highlighted retatrutide, Lilly’s triple-hormone candidate, which has produced greater average weight loss than Zepbound in trials and could be filed with the FDA in 2027. Potential applications in fatty liver disease, sleep apnea and other conditions could expand the addressable market. Lilly retatrutide article
• Positive Sentiment: Foundayo data strengthened the oral GLP-1 opportunity. Lilly presented analysis showing its oral GLP-1 candidate delivered greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes. A successful oral product could improve convenience, broaden adoption and support future revenue growth, although the analysis has limitations and competition remains intense. Foundayo data article
• Positive Sentiment: Investors are seeing growth beyond weight loss. Commentary pointed to emerging contributions from Lilly’s oncology, immunology and neuroscience portfolios, as well as progress in early-stage programs including basal insulin and elt??rekibart. The breadth of the pipeline supports the view that Lilly is more than a single-product obesity story. Lilly pipeline growth article
• Neutral Sentiment: Momentum is building ahead of third-quarter earnings. Recent commentary cited strong sales growth, favorable expectations and technical momentum. Lilly’s latest reported quarter substantially exceeded analyst estimates, but investors will look for continued execution and guidance support at the next earnings release. Lilly earnings momentum article
• Negative Sentiment: Valuation leaves limited room for disappointment. With LLY valued near 40 times trailing earnings and carrying a market capitalization above $1 trillion, analysts warned that much of the GLP-1 growth outlook is already reflected in the stock. Pricing pressure, reimbursement challenges and the long regulatory path for new drugs could create volatility. Lilly valuation article
• Negative Sentiment: New WHO childhood-obesity guidelines may add pressure. The guidelines discourage weight-loss medication use as a standalone solution for children and adolescents, emphasizing broader interventions. That could constrain or delay one potential expansion area for Lilly and Novo Nordisk, although the direct near-term revenue impact is uncertain. WHO childhood obesity guidelines article

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Sanford C. Bernstein upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. TD Cowen reissued a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Finally, Guggenheim upped their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,312.36.

Eli Lilly and Company Trading Up 2.5%

The business’s 50 day simple moving average is $1,173.98 and its 200 day simple moving average is $1,092.69. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 39.83, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts anticipate that Eli Lilly and Company will post 36.66 EPS for the current year.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently made changes to their positions in LLY. S.E.E.D. Planning Group LLC purchased a new position in Eli Lilly and Company during the 3rd quarter valued at about $252,000. Benedict Financial Advisors Inc. grew its position in shares of Eli Lilly and Company by 67.0% in the third quarter. Benedict Financial Advisors Inc. now owns 304 shares of the company’s stock valued at $352,000 after purchasing an additional 122 shares during the last quarter. MRA Advisory Group grew its position in shares of Eli Lilly and Company by 194.2% in the third quarter. MRA Advisory Group now owns 859 shares of the company’s stock valued at $994,000 after purchasing an additional 567 shares during the last quarter. Lake Hills Wealth Management LLC purchased a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $1,058,000. Finally, Worth Asset Management LLC raised its position in shares of Eli Lilly and Company by 9.4% during the 3rd quarter. Worth Asset Management LLC now owns 1,786 shares of the company’s stock worth $2,067,000 after purchasing an additional 153 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.